Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs Tesla, Inc. (TSLA) Price & Performance

AbCellera Biologics IncTrade
Tesla, Inc.Trade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs Tesla, Inc. — how do they compare? AbCellera Biologics Inc trades at $9.03 (market cap $2.85B), while Tesla, Inc. trades at $334.17 (market cap $1.31T). The key difference: Tesla, Inc. is far larger — about 459.6× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Tesla, Inc. nearer its low. Which is the better fit depends on your goals.

ABCLTSLA
Market Cap
$2.85B$1.31T
Sector
HealthConsumer Cyclical
52-Week High
$9.76$489.88
52-Week Low
$2.78$298.16
Enterprise Value
$2.45B$1.28T

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.

The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.

Tesla, Inc.

Tesla (TSLA) trades at $330.87, up 0.7% today, amid mixed signals: technicals are bearish with support at $327 and resistance at $333, while fundamentals show elevated valuation ratios (P/E 306.37) but recent earnings beats. Revenue dipped to $94.83B in 2025, with net margin at 3.67%, as the company pivots toward AI and robotics. News highlights regulatory approval for self-driving software in Europe (Reuters, 2026-04-10) and a 315% surge in German registrations (Zacks, 2026-04-10).

Outlook: Tesla's stock faces headwinds from high valuation and slowing auto growth, but opportunities exist in AI and energy expansion. Risks include intense EV competition and execution challenges. Analysts are divided, with a consensus price target of $393.87 (40.74% buy ratings), suggesting cautious optimism if innovation delivers.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About Tesla, Inc.

Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.

Read more on TSLA